-
Electronic (PDF)
-
Site License
-
Enterprisewide
Post-Myocardial Infarction - Pipeline Review, H1 2012
Global Markets Direct, May 2012, Pages: 26
Post-Myocardial Infarction – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Post-Myocardial Infarction - Pipeline Review, H1 2012', provides an overview of the Post-Myocardial Infarction therapeutic pipeline. This report provides information on the therapeutic development for Post-Myocardial Infarction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Myocardial Infarction. 'Post-Myocardial Infarction - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Post-Myocardial Infarction.
- A review of the Post-Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Post-Myocardial Infarction pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Post-Myocardial Infarction.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Post-Myocardial Infarction pipeline depth and focus of Post-Myocardial Infarction therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Post-Myocardial Infarction Therapeutic Products under Development, Key Players in Post-Myocardial Infarction Therapeutics, Post-Myocardial Infarction Pipeline Overview, Post-Myocardial Infarction Pipeline, Post-Myocardial Infarction Pipeline Assessment
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post-Myocardial Infarction Overview
Therapeutics Development
An Overview of Pipeline Products for Post-Myocardial Infarction
Post-Myocardial Infarction Therapeutics under Development by Companies
Post-Myocardial Infarction Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Post-Myocardial Infarction Therapeutics – Products under Development by Companies
Post-Myocardial Infarction Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Post-Myocardial Infarction Therapeutics Development
miRagen Therapeutics, Inc.
Post-Myocardial Infarction – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Molecule Type
Drug Profiles
Natrecor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGN-1374 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Post-Myocardial Infarction Therapeutics – Drug Profile Updates
Post-Myocardial Infarction – Product Development Milestones
Featured News & Press Releases
Sep 28, 2010: Trophos Initiates Clinical Development Of TRO40303
Mar 02, 2009: RegeneRx Completes Enrollment And Dosing Of Phase I Safety Trial For Potential Heart Drug
Sep 22, 2008: RegeneRx Enrolls First Subject In RGN-352 Phase IB Clinical Trial
Sep 08, 2008: RegeneRx Successfully Completes Phase IA Clinical Trial
Jul 03, 2008: RegeneRx Completes Enrollment And Dosing Of Phase IA Safety Trial For Potential Heart Drug
Feb 15, 2008: King Pharmaceuticals Announces Altace Tablets Launch
May 19, 2007: King Pharmaceuticals Reports Efficacy of Altace 20mg and Efficacy of a Combination of Altace 20mg and Hydrochlorothiazide 25mg for 24-Hour Blood Ppressure Control
May 08, 2007: King Pharmaceuticals Announces Plan to Present Results From Phase III Clinical Trial Evaluating Altace As Monotherapy And In Combination With Hydrochlorothiazide At The American Society Of Hypertension Annual Meeting
Apr 19, 2007: King Pharmaceuticals Announces Plan to Report Positive Data From Phase III Clinical Trial Evaluating the Combination of Altace With Hydrochlorothiazide
Feb 28, 2007: King Pharmaceuticals Announces FDA Approval of Altace Tablet Formulation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Post-Myocardial Infarction, H1 2012
Products under Development for Post-Myocardial Infarction – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
miRagen Therapeutics, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Post-Myocardial Infarction Therapeutics – Drug Profile Updates
List of Figures
Number of Products under Development for Post-Myocardial Infarction, H1 2012
Products under Development for Post-Myocardial Infarction – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Mid Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
